# Protagonist Therapeutics Inc. (PTGX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $145.72, market value $9.4 billion.

## Valuation
- **P/E (trailing): 141.5×** (5-yr avg 9.1×, 3-yr avg 9.1×). Protagonist Therapeutics Inc. trades at 141.5× trailing earnings, well above its own five-year average of 9.1×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 33.4×**. Each dollar of revenue is priced at 33.4×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 11.2×**. The shares trade at 11.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 155.5×**. Enterprise value is 155.5× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 1.4%** (5-yr avg -4.9%). Free cash flow equals 1.4% of the market value, above its five-year average of -4.9%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 0.7%**. The inverse of the P/E: 0.7% of the price is earned each year.

## Profitability
- **Operating margin: 20.7%**. 20.7% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: -282.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: -21.2%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 9.3%**. Return on all capital, debt included, is 9.3%.
- **Return on assets: 12.4%**. Each dollar of assets produces 12.4% of profit.

## Growth
- **Revenue growth (1 yr): -89.4%** (3-yr 20.1%/yr, 5-yr 10.0%/yr). Revenue fell 89.4% over the last year, against 10.0% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -148.5%**. Earnings per share fell 148.5%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.02**. Debt is 0.02 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Protagonist Therapeutics Inc. holds more cash than debt.
- **Current ratio: 12.71** (quick 12.71). Current assets cover the next year's liabilities 12.71 times.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Protagonist Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (13 analysts). 13 analysts cover Protagonist Therapeutics Inc.; the consensus is strong_buy, with an average price target of $174.69 (+20% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 144.5%** (YTD 66.8%, 3-mo 49.6%). The shares are up 144.5% over twelve months including dividends.
- **From 52-week high: -9.4%** (167.4% above the low). Trading 9% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 0.19** (volatility 51%). Beta of 0.19 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PTGX · Page: https://foliofundamentals.com/stocks/ptgx

Not investment advice.